Evecxia Therapeutics—the first company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification to treat CNS disorders—today announced Dr. Jacob Pade Ramsøe Jacobsen, the Co-Founder & Chief Executive Officer of Evecxia Therapeutics, Inc., will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024.
Link to ACCESS CHINA.
About Evecxia Therapeutics
Evecxia is the first company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification to treat CNS disorders. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression and obsessive-compulsive disorder (OCD) when first-line serotonin reuptake inhibitor (SSRI/SNRI) antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients hospitalized for acute suicidal crisis.
For additional information about Evecxia, please visit www.evecxia.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918360574/en/
Contacts
Jacob Jacobsen, CEO
Evecxia Therapeutics, Inc.
Info@evecxia.com
